The HLA class I major histocompatibility complex is crucial for immune surveillance and is being explored for cancer immunotherapy. Previous work demonstrated the efficacy of peptide vaccines in B-HLA-A2.1 mice, now extended to NY-ESO-1 and WT1-Db126 peptides, reducing tumor volume in the latter case. Two new humanized HLA models, B-HLA-A11.1 and B-HLA-A24.2 mice, were generated, showing successful HLA expression and immune response to peptide SART2 93-101 in B-HLA-A24.2 mice. These models serve as valuable tools for evaluating novel peptide vaccines.